SK Capital Partners have signed a definitive agreement to divest the Noramco API related assets in a sale to Siegfried (Zofingen Switzerland) -- The transaction is subject to customary closing ...
PMMI research shows pharmaceutical manufacturers face a growing market and will need OEMs and suppliers to overcome ...
For much of the past decade, drug shortages in the United States were treated as episodic disruptions. In 2024, that framing ...
Regulatory authorities in China have cracked down on Sun Pharma’s rivastigmine-based Alzheimer’s disease treatment, halting ...
Tariffs and significant US manufacturing investments complicate ROI calculations and increase operational costs, challenging ...
PMMI research identifies top manufacturing hurdles including regulatory compliance, automation needs, and sustainability priorities ...
Laine Mello, director of Marketing at Ecolab for its bioprocessing business, shares her insights on the digital ...
Agno Pharma, a global contract development and manufacturing organization (CDMO) specializing in small-molecule active ...
While the threat of U.S. import tariffs prompted a surge in drug production last year, that output is slated to slow across multiple geographies in 2026. | While the threat of U.S. import tariffs ...
In today’s Pharmaceutical Executive Daily, tariff uncertainty triggers a short-term surge in pharmaceutical manufacturing ...
While there were outliers, Marston said a major chunk of the investments are concentrated in a few key hubs: Pennsylvania and ...
SAN DIEGO, CA - January 27, 2026 (NEWMEDIAWIRE) - Quantumzyme Corp. (OTC: QTZM), a biotransformation company focused on sustainable pharmaceutical manufacturing, today announced a breakthrough ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results